Effects of adenosine receptor antagonists on the in vivo lps-induced inflammation model of parkinson's disease

Neurotoxicity Research

Volumn 24, Issue 1, 2013, Pages 29-40

  Gołembiowska, Krystyna ^a   Wardas, Jadwiga ^a   Noworyta Sokołowska, Karolina ^a   Kamińska, Katarzyna ^a   Górska, Anna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Adenosine A2A receptor antagonists; Inflammation; Oxidative stress; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ADENOSINE; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; CAFFEINE; DOPAMINE; GLUTAMIC ACID; HOMOVANILLIC ACID; HYDROXYL RADICAL; ISTRADEFYLLINE; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DRUG DOSE COMPARISON; IN VIVO STUDY; MALE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; RECEPTOR DENSITY; SUBSTANTIA NIGRA;

ADENOSINE; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CAFFEINE; CORPUS STRIATUM; DOPAMINE; DOPAMINERGIC NEURONS; GLUTAMIC ACID; HYDROXYL RADICAL; INFLAMMATION; LIPOPOLYSACCHARIDES; MALE; MICROINJECTIONS; PARKINSON DISEASE; PURINES; RATS; RECEPTOR, ADENOSINE A2A;

RATTUS;

EID: 84878349327     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-012-9372-1     Document Type: Article

References (64)

1. Aguiar LMV, Nobre HV Jr, Macêdo DS, Oliveira AA, Freitas RM, Vasconcelos SM, Cunha GMA, Sousa FCF, Viana GSB (2006) Neuroprotective effect of caffeine in the model of 6-hydroxydopamine lesion in rats. Pharmacol Biochem Behav 84:415-419
2. Aoyama K, Matsumura N, Watabe M, Wang F, Kikuchi-Utsumi K, Nakaki T (2011) Caffeine and uric acid mediate glutathione synthesis for neuroprotection. Neuroscience 181:206-215
3. Ascherio A, Zhang SH, Hernán MA, Kawachi I, Colditz GA, Speizer FE, Willett WC (2001) Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50:56-63
4. Barger SW, Goodwin ME, Porter MM, Beggs ML (2007) Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J Neurochem 101:1205-1213
5. Bezzi P, Gundersen V, Galbete JL, Seifert G, Steinhäuser C, Pilati E, Volterra A (2004) Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamate. Nat Neurosci 7:613-620
6. 2A adenosine receptor inhibits nitric oxide production in glial cells. FEBS Lett 429:139-142
7. Brothers HM, Marchalant Y, Wenk GL (2010) Caffeine attenuates lipopolysaccharide-induced neuroinflammation. Neurosci Lett 480:97-100
8. 2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog Neurobiol 83:310-331
9. 2A receptor blockade. Purinergic Sig 1:111-134
10. Członkowska A, Kohutnicka M, Kurkowska-Jastrzȩbska I, Członkowski A (1996) Microglial reaction in MPTP (1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5:137-143
11. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909
12. Duke DC, Moran LB, Pearce RK, Graeber MB (2007) The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics 8:83-94
13. Dunwiddie TV, Fredholm BB (1997) Adenosine neuromodulation. In: Jacobson KA, Jarvis MF (eds) Purinergic approaches in experimental therapeutics. Wiley-Liss, Inc., New York, pp 359-382
14. 2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats. Eur J Pharmacol 321:143-147
15. Fiebich BL, Biber K, Lieb K, Calker D, Berger M, Bauer J, Gebicke-Haerter PJ (1996) Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 18:152-160
16. Gao HM, Jiang J, Wilson B, Zhang W, Hong JS, Liu B (2002) Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem 81:1285-1297
17. Gao HM, Hong JS, Zhang W, Liu B (2003) Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci 23:1228-1236
18. 11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobil Dis 21:404-412
19. 2A receptor antagonists and l-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats. Neurotox Res 21:222-230
20. 2A receptor antagonists on hydroxyl radical, glutamate and dopamine in the striatum of rats with altered function of VMAT2. Neurotox Res 22:150-157
21. Gołembiowska K, Dziubina A, Kowalska M, Kamińska K (2008) Paradoxical effects of adenosine receptor ligands on hydroxyl radical generation by l-DOPA in the rat striatum. Pharmacol Rep 60:319-330
22. 2A receptor antagonists on l-DOPA-induced hydroxyl radical formation in rat striatum. Neurotox Res 15:155-166
23. Haskó G, Pacher P, Vizi ES, Illes P (2005) Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci 26:511-516
24. Hauber W, Neuscheler P, Nagel J, Muller CE (2001) Catalepsy induced by blockade of dopamine D1 or D2 receptors was reversed by concomitant blockade of adenosine A(2A) receptors in caudate-putamen of rats. Eur J Neurosci 14:1287-1293
25. Heese K, Fiebich BL, Bauer J, Otten U (1997) Nerve growth factor (NGF) expression in rat microglia is induced by adenosine A2a-receptors. Neurosci Lett 231:83-86
26. Hirsh EC, Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8:382-397
27. Hunter RL, Dragicevic N, Seifert K, Choi DY, Liu M, Kim HC, Cass WA, Sullivan PG, Bing G (2007) Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. J Neurochem 100:1375-1386
28. 3H]CGS 21680 to rat brain using autoradiography. Neuropharmacology 34:393-403
29. 2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43:507-513
30. 2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 162:321-327
31. Knecht R, Chang JY (1986) Liquid chromatographic determination of amino acids after gas-phase hydrolysis and derivatization with (dimethylamino) azobenzenesulfonyl chloride. Anal Chem 58:2375-2379
32. Knott C, Stern G, Wilkin GP (2000) Inflammatory regulators in Parkinson's disease: iNOS, Lipocortin-1, and cyclooxygenase-1 and-2. Mol Cell Neurosci 16:724-739
33. Kot M, Daniel WA (2008) Caffeine as a marker substrate for testing cytochrome P450 activity in human and rat. Pharmacol Rep 60:789-797
34. 2A adenosine receptors. Life Sci 68:1343-1350
35. McGeer PL, Schwab C, Parent A, Doudet D (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration. Ann Neurol 54:599-604
36. Mogi M, Togari A, Tanaka K, Ogawa N, Ichinose H, Nagatsu T (2000) Increase in level of tumor necrosis factor-alpha in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506. Neurosci Lett 289:165-168
37. Nakamura Y (2002) Regulating factors for microglial activation. Biol Pharm Bull 25:945-953
38. 2A adenosine receptors. Glia 39:133-147
39. 2A antagonists, offer neuroprotection against 6-OHDA-induced neurotoxicity in rat mesencephalic cells. Neurochem Int 56:51-58
40. Noschang CG, Krolow R, Pettenuzzo LF, Ávila MC, Fachin A, Arcego D, Toigo EP, Crema LM, Diehl LA, Vendite D, Dalmaz C (2009) Interactions between chronic stress and chronic consumption of caffeine on the enzymatic antioxidant system. Neurochem Res 34:1568-1574
41. Ochi M, Koga K, Kurokawa M, Kase H, Nakamura J, Kuwana Y (2000) Systemic administration of adenosine A2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: a microdialysis study. Neuroscience 100:53-62
42. Ogata T, Schubert P (1996) Programmed cell death in rat microglia is controlled by extracellular adenosine. Neurosci Lett 218:91-94
43. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic Press, San Diego
44. 2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors. J Neurochem 89:152-156
45. Pollack AE, Fink JS (1995) Adenosine antagonists potentiate D2 dopamine-dependent activation of Fos in the striatopallidal pathway. Neuroscience 68:721-728
46. Popoli P, Blum D, Pintor A, Tebano MT, Frank C, Gianfriddo M, Domenici MR, Schiffmann SN, Pedata F (2004) The controversial role of adenosine receptor antagonists as neuroprotective agents. Curr Med Chem Centr Nerv Sys Agents 4:35-45
47. Przedborski S, Leviver M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki DM (1995) Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67:631-647
48. Qin L, Liu Y, Cooper C, Liu B, Wilson B, Hon JS (2002) Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J Neurochem 83:973-983
49. Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B, Liu B, Hong JS (2004) NADPH Oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 279:1415-1421
50. Rose S, Ramsay Croft N, Jenner P (2007) The novel A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats. Brain Res 1133:110-114
51. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung K-H, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR (2000) Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283:2674-2679
52. Rowe DB, Le W, Smith RG, Appel SH (1998) Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. J Neurosci Res 53:551-558
53. 2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem 95:919-929
54. Schousboe A, Waagepetersen HS (2005) Role of astrocytes in glutamate homeostasis: implications for excitotoxicity. Neurotox Res 8:221-225
55. 2A receptors in Parkinson's disease. Trends Neurosci 29:647-654
56. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology 147:90-95
57. Streit WJ, Xue QS (2009) Life and death of microglia. J Neuroimmune Pharmacol 4:371-379
58. 2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission. Neuropharmacology 53:783-789
59. van den Berg D, Zoellner KR, Ogunrombi MO, Malan SF, Blanche GT, Castagnoli N Jr, Bergh JJ, Petzer JP (2007) Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues. Bioorg Med Chem 15:3692-3702
60. Verkhratsky A, Butt A (2007) Glial neurobiology. Wiley, Chichester
61. Volterra A, Meldolesi J (2005) Astrocytes, from brain glue to communication elements: the revolution continues. Nature Rev Neurosci 6:626-640
62. Whitton PS (2007) Inflammation as a causative factor in the aetiology of Parkinson's disease. Brit J Pharmacol 150:963-976
63. 2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol 63:338-346
64. Zhang Q, Haydon PG (2005) Roles for gliotransmission in the nervous system. J Neural Transm 112:121-125